CU6 Stock Overview
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Clarity Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.84 |
| 52 Week High | AU$1.05 |
| 52 Week Low | AU$0.36 |
| Beta | 0 |
| 1 Month Change | -15.15% |
| 3 Month Change | 21.74% |
| 1 Year Change | 14.29% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -44.00% |
Recent News & Updates
Shareholder Returns
| CU6 | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -5.1% | -4.4% | 0.6% |
| 1Y | 14.3% | -25.2% | 3.5% |
Return vs Industry: CU6 exceeded the Australian Pharmaceuticals industry which returned -25.2% over the past year.
Return vs Market: CU6 exceeded the Australian Market which returned 3.5% over the past year.
Price Volatility
| CU6 volatility | |
|---|---|
| CU6 Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: CU6 is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CU6's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Colin Biggin | https://www.claritypharmaceuticals.com |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.
Clarity Pharmaceuticals Ltd Fundamentals Summary
| CU6 fundamental statistics | |
|---|---|
| Market Cap | AU$218.12m |
| Earnings (TTM) | -AU$23.75m |
| Revenue (TTM) | AU$6.46m |
33.8x
P/S Ratio-9.2x
P/E RatioIs CU6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CU6 income statement (TTM) | |
|---|---|
| Revenue | AU$6.46m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$6.46m |
| Other Expenses | AU$30.21m |
| Earnings | -AU$23.75m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.091 |
| Gross Margin | 100.00% |
| Net Profit Margin | -367.78% |
| Debt/Equity Ratio | 0% |
How did CU6 perform over the long term?
See historical performance and comparison